Related Experiment Video

Updated: Jun 21, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

A novel tumor-targeted therapy using a claudin-4-targeting molecule

Rie Saeki1, Masuo Kondoh, Hideki Kakutani

  • 1Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan.

Molecular Pharmacology
|July 30, 2009
PubMed

Insights

A novel claudin-4-targeting therapy using C-CPE-PSIF shows promise against cancer. This approach leverages a fusion protein to selectively target claudin-4, reducing tumor growth and offering a potential new strategy for malignant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Carcinogenesis is linked to disrupted tight junctions (TJs) and loss of cellular polarity.
  • Claudin-4 is frequently deregulated in various cancers, presenting a potential therapeutic target.
  • Current claudin-targeting strategies for tumor therapy are underdeveloped.

Purpose of the Study:

  • To develop and evaluate a novel claudin-4-targeting molecule for cancer therapy.
  • To assess the cytotoxicity and specificity of the engineered molecule.
  • To investigate the therapeutic potential of claudin-4 targeting in vivo.

Main Methods:

  • Fusion of Clostridium perfringens enterotoxin C-terminal fragment (C-CPE) with Pseudomonas aeruginosa exotoxin-derived protein synthesis inhibitory factor (PSIF).
  • Assessment of cytotoxicity in cells expressing different claudin types and varying TJ development.
  • Evaluation of C-CPE-PSIF efficacy via intratumoral injection in a tumor model.

Main Results:

  • The C-CPE-PSIF fusion molecule demonstrated selective cytotoxicity against claudin-4-expressing cells.
  • Cells expressing claudins-1, -2, and -5 showed reduced sensitivity to C-CPE-PSIF.
  • Intratumoral administration of C-CPE-PSIF effectively reduced tumor growth.
  • Polarity and TJ development influenced cellular sensitivity to the C-CPE-PSIF molecule.

Conclusions:

  • Claudin-4 targeting represents a promising therapeutic strategy for malignant tumors.
  • The C-CPE-PSIF molecule exhibits targeted cytotoxicity and anti-tumor effects.
  • Further development of claudin-targeting therapies holds potential for cancer treatment.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...